[go: up one dir, main page]

SE9600436D0 - Vaccine against hantavirus - Google Patents

Vaccine against hantavirus

Info

Publication number
SE9600436D0
SE9600436D0 SE9600436A SE9600436A SE9600436D0 SE 9600436 D0 SE9600436 D0 SE 9600436D0 SE 9600436 A SE9600436 A SE 9600436A SE 9600436 A SE9600436 A SE 9600436A SE 9600436 D0 SE9600436 D0 SE 9600436D0
Authority
SE
Sweden
Prior art keywords
vaccine against
cell
amino
against hantavirus
sequences
Prior art date
Application number
SE9600436A
Other languages
Swedish (sv)
Inventor
Aake Lundkvist
Original Assignee
Aake Lundkvist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aake Lundkvist filed Critical Aake Lundkvist
Priority to SE9600436A priority Critical patent/SE9600436D0/en
Publication of SE9600436D0 publication Critical patent/SE9600436D0/en
Priority to AU17401/97A priority patent/AU1740197A/en
Priority to PCT/SE1997/000180 priority patent/WO1997028819A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus vaccine against Hantaviruses, especially Puumala virus, which comprises, an immunizing component, at least one member of the group consisting of: a) a recombinant protein having the amino-acid sequence of the figure; b) fragments of said protein which comprise B-cell and/or T-cell epitopes; and c) amino-acid sequences which are at least 80 % homologous to the sequences of a) or b) and which comprise B-cell and/or T-cell epitopes, are disclosed.
SE9600436A 1996-02-06 1996-02-06 Vaccine against hantavirus SE9600436D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9600436A SE9600436D0 (en) 1996-02-06 1996-02-06 Vaccine against hantavirus
AU17401/97A AU1740197A (en) 1996-02-06 1997-02-06 Vaccine against hantavirus
PCT/SE1997/000180 WO1997028819A1 (en) 1996-02-06 1997-02-06 Vaccine against hantavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600436A SE9600436D0 (en) 1996-02-06 1996-02-06 Vaccine against hantavirus

Publications (1)

Publication Number Publication Date
SE9600436D0 true SE9600436D0 (en) 1996-02-06

Family

ID=20401291

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600436A SE9600436D0 (en) 1996-02-06 1996-02-06 Vaccine against hantavirus

Country Status (3)

Country Link
AU (1) AU1740197A (en)
SE (1) SE9600436D0 (en)
WO (1) WO1997028819A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100011D0 (en) * 2001-01-03 2001-01-03 Eurocine Ab Karolinska Inst Sc Virus vaccine formulation
WO2018017922A2 (en) 2016-07-22 2018-01-25 Massachusetts Institute Of Technology Selective bfl-1 peptides
EP3852783A1 (en) * 2018-09-17 2021-07-28 Massachusetts Institute of Technology Peptides selective for bcl-2 family proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837441A (en) * 1993-08-25 1998-11-17 University Of New Mexico Hantavirus-associated respiratory distress virus antigens

Also Published As

Publication number Publication date
WO1997028819A1 (en) 1997-08-14
AU1740197A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
HUP9901186A2 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
ATE418562T1 (en) CTL EPITOPES OF THE EPSTEIN-BARR VIRUS
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DK1278534T3 (en) Methods and compositions for attenuating the multiplication of HIV-1
PH25747A (en) Recombinant vaccinia vrus mva
ATE267211T1 (en) VACCINE AGAINST HPV
DK0835133T3 (en) Recombinant smallpox virus rabies and combination preparations and their uses
ATE312920T1 (en) DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION
DE60039050D1 (en) ANTIGENIC MENINGOCOCKS PEPTIDES
DE69636285D1 (en) ISOLATED FRPB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE
DE69738512D1 (en) EPSTEIN-BARR VIRUS TYPE B CTL EPITOPES
ATE234628T1 (en) THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH INCOMPLETE CELLULAR PEPTIDE PROCESSING, E.G.: EXPRESSED IN RMA-S CELLS TRANSFECTED WITH B7-1 GENE
EA200100395A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
SE9600436D0 (en) Vaccine against hantavirus
RU93048174A (en) AVIRULENT VACCINE AGAINST RABIES AND METHOD FOR ITS OBTAINING
ATE435034T1 (en) EXPRESSION AND CHARACTERIZATION OF AN HIV-1 ENVELOPE PROTEIN ASSOCIATED WITH A BROADLY REACTIVE NEUTRALIZING ANTIBODY RESPONSE.
DK0938329T3 (en) Immunogenic TLP composition
DK0831881T3 (en) CETP to increase HDL cholesterol levels
DE69126486D1 (en) INDUCTION OF PROTECTION AGAINST VIRAL INFECTION
FR2724385B1 (en) FELINE INFECTIOUS PERITONITIS VACCINE.
DE69433057D1 (en) PEPTIDES FOR USE IN VACCINATING AND INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNE VIRUS
DE69726602D1 (en) Hepatitis b inhibitoren
TR200202169T1 (en) Purified hepatitis C virus envelope proteins for use in diagnosis and treatment.
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
NO20042124L (en) Thymosin enhancement by genetic immunization